Cramer’s Three Biotech Picks, And His Biotech Strategy
by Jon C. Ogg
24/7 Wall St.
Jim Cramer has a video on TheStreet.com “Wall St. Confidential” showing how the biotech sector can be looked at with blow-ups. For every small biotech that grown up into a huge company there are 100 Northfield Labs (NFLD). Cramer thinks you have to play momentum and even stocks like Genentech (DNA) and Amgen (AMGN) have to be gotten out when they are no longer going up.
Cramer still likes Celgene (CELG), Gilead (GILD) and Genzyme (GENZ) in the sector. If you bet on one product wonders then have you to be prepared to lose everything. Onyx Pharma (ONXX) is a potential one-hit wonder that Cramer likes, but says to play it you should buy deep in the money calls because any bad news could chop the stock in half. He also noted that he believes the FDA is not predictable on upcoming drugs.
Continue article at 247WallSt.com
RELATED READING:
- Northfield Labs Heads Permanently South
- Cramer’s Obesity Stock Plays
- Cramer’s Newest Laser Pick: Cynosure
___________________
Comments
Leave a Reply
You must be logged in to post a comment.